217 related articles for article (PubMed ID: 28723234)
1. Flexible small molecular anti-estrogens with N,N-dialkylated-2,5-diethoxy-4-morpholinoaniline scaffold targets multiple estrogen receptor conformations.
Asare BK; Yawson E; Rajnarayanan RV
Cell Cycle; 2017 Aug; 16(15):1465-1477. PubMed ID: 28723234
[TBL] [Abstract][Full Text] [Related]
2. A new class of small molecule estrogen receptor-alpha antagonists that overcome anti-estrogen resistance.
Ma Y; Preet A; Tomita Y; De Oliveira E; Zhang L; Ueda Y; Clarke R; Brown M; Rosen EM
Oncotarget; 2015 Dec; 6(38):40388-404. PubMed ID: 26575173
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
[TBL] [Abstract][Full Text] [Related]
4. A naringenin-tamoxifen combination impairs cell proliferation and survival of MCF-7 breast cancer cells.
Hatkevich T; Ramos J; Santos-Sanchez I; Patel YM
Exp Cell Res; 2014 Oct; 327(2):331-9. PubMed ID: 24881818
[TBL] [Abstract][Full Text] [Related]
5. Discovery at the interface: Toward novel anti-proliferative agents targeting human estrogen receptor/S100 interactions.
Lee DH; Asare BK; Rajnarayanan RV
Cell Cycle; 2016 Oct; 15(20):2806-18. PubMed ID: 27580430
[TBL] [Abstract][Full Text] [Related]
6. Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant.
Planas-Silva MD; Waltz PK; Kilker RL
J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):193-8. PubMed ID: 16464573
[TBL] [Abstract][Full Text] [Related]
7. Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors.
Suba Z
Recent Pat Anticancer Drug Discov; 2018; 13(4):428-444. PubMed ID: 30027855
[TBL] [Abstract][Full Text] [Related]
8. Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes: synthesis, structure-activity relationships and molecular modeling study for flexible estrogen receptor antagonists.
Lloyd DG; Smith HM; O'Sullivan T; Knox AS; Zisterer DM; Meegan MJ
Med Chem; 2006 Mar; 2(2):147-68. PubMed ID: 16787364
[TBL] [Abstract][Full Text] [Related]
9. EPRS is a critical regulator of cell proliferation and estrogen signaling in ER+ breast cancer.
Katsyv I; Wang M; Song WM; Zhou X; Zhao Y; Park S; Zhu J; Zhang B; Irie HY
Oncotarget; 2016 Oct; 7(43):69592-69605. PubMed ID: 27612429
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptors: selective ligands, partners, and distinctive pharmacology.
Katzenellenbogen BS; Montano MM; Ediger TR; Sun J; Ekena K; Lazennec G; Martini PG; McInerney EM; Delage-Mourroux R; Weis K; Katzenellenbogen JA
Recent Prog Horm Res; 2000; 55():163-93; discussion 194-5. PubMed ID: 11036937
[TBL] [Abstract][Full Text] [Related]
11. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
McDaniel RE; Maximov PY; Jordan VC
Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
[TBL] [Abstract][Full Text] [Related]
12. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.
Montano MM; Ekena K; Krueger KD; Keller AL; Katzenellenbogen BS
Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652
[TBL] [Abstract][Full Text] [Related]
13. Nuclear and extranuclear-initiated estrogen receptor signaling crosstalk and endocrine resistance in breast cancer.
Kulkoyluoglu E; Madak-Erdogan Z
Steroids; 2016 Oct; 114():41-47. PubMed ID: 27394959
[TBL] [Abstract][Full Text] [Related]
14. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer.
Lykkesfeldt AE
Acta Oncol; 1996; 35 Suppl 5():9-14. PubMed ID: 9142958
[TBL] [Abstract][Full Text] [Related]
16. Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351.
Levenson AS; MacGregor Schafer JI; Bentrem DJ; Pease KM; Jordan VC
J Steroid Biochem Mol Biol; 2001; 76(1-5):61-70. PubMed ID: 11384864
[TBL] [Abstract][Full Text] [Related]
17. Estrogenic and antiestrogenic regulation of the half-life of covalently labeled estrogen receptor in MCF-7 breast cancer cells.
BorrĂ¡s M; Laios I; el Khissiin A; Seo HS; Lempereur F; Legros N; Leclercq G
J Steroid Biochem Mol Biol; 1996 Feb; 57(3-4):203-13. PubMed ID: 8645630
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic insight of drug resistance with special focus on iron in estrogen receptor positive breast cancer.
Mittal R; Chaudhry N; Pathania S; Mukherjee TK
Curr Pharm Biotechnol; 2014; 15(12):1141-57. PubMed ID: 25429654
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting in the estrogen receptor hormonal pathway.
Katzenellenbogen BS; Frasor J
Semin Oncol; 2004 Feb; 31(1 Suppl 3):28-38. PubMed ID: 15052541
[TBL] [Abstract][Full Text] [Related]
20. Estrogen-dependent rapid activation of protein kinase C in estrogen receptor-positive MCF-7 breast cancer cells and estrogen receptor-negative HCC38 cells is membrane-mediated and inhibited by tamoxifen.
Boyan BD; Sylvia VL; Frambach T; Lohmann CH; Dietl J; Dean DD; Schwartz Z
Endocrinology; 2003 May; 144(5):1812-24. PubMed ID: 12697687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]